Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
influenza vaccine Fluarix, Adjuvanted Fluarix · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| influenza vaccine Fluarix, Adjuvanted Fluarix | BIOLOGICAL | - |
Inclusion Criteria: * A male or female aged over 65 years at the time of the revaccination; who previously received the adjuvanted candidate vaccine or Fluarix during a clinical study organized during the preceeding year Exclusion Criteria: * Use of any investigational or non-registered product (...
Influenza vaccine Fluarix, Adjuvanted Fluarix is used to prevent influenza disease. It is being studied in the elderly population, specifically in adults aged 65 years and older, to assess its safety as a candidate vaccine against influenza.
Influenza vaccine Fluarix, Adjuvanted Fluarix is developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this vaccine candidate for the prevention of influenza.
Influenza vaccine Fluarix, Adjuvanted Fluarix is in Phase 1 clinical development. It is an investigational vaccine candidate and is not yet approved for use. One Phase 1 trial has been completed to evaluate its safety.
Influenza vaccine Fluarix, Adjuvanted Fluarix has one completed clinical trial, NCT00318058, titled 'Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population.' This Phase 1 study enrolled 84 healthy volunteers aged 65 years and older in Belgium.
Influenza vaccine Fluarix, Adjuvanted Fluarix is an adjuvanted version of the influenza vaccine Fluarix. The adjuvanted formulation is being studied specifically for use in the elderly population to potentially enhance the immune response compared to the standard vaccine.